Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults

Abstract 

Respiratory syncytial virus (RSV) stands as a significant contributor to acute respiratory infection, lower respiratory tract disease, clinical complications, and mortality in older adults. Despite its impact, there is currently no licensed vaccine against RSV infection. The RSVPreF3 OA vaccine, funded by GlaxoSmithKline Biologicals (ClinicalTrials.gov number, NCT04886596), demonstrated an acceptable safety profile and notable efficacy. Administered in a single dose, it effectively prevented RSV-related acute respiratory infection, lower respiratory tract disease, and severe RSV-related lower respiratory tract disease in individuals aged 60 or older. Impressively, this protection extended across RSV subtypes and was effective regardless of the presence of underlying coexisting conditions.